Risk Factors and impact of Allergic Bronchopulmonary Aspergillosis in P. aeruginosa negative CF Patients.

Risk Factors and impact of Allergic Bronchopulmonary Aspergillosis in P. aeruginosa negative CF Patients.

Pediatr Allergy Immunol. 2018 Jul 07;:

Authors: De Baets F, De Keyzer L, Van Daele S, Schelstraete P, Van Biervliet S, Van Braeckel E, Thomas M, Wanyama SS

Abstract
BACKGROUND: Allergic Bronchopulmonary aspergillosis (ABPA) is a major complication in CF patients. Risk factors for ABPA and clinical deterioration in CF patients, negative for Pseudomonas aeruginosa (Pa), were explored.
METHODS: We performed a retrospective case-control study in 73 Pa-negative patients. Each patient was matched with 2 controls for age, gender, pancreas sufficiency, CFTR mutation (homozygous or heterozygous deltaF508) and Pa colonization.
RESULTS: Median FEV1 at the year of diagnosis (index year) was significantly lower in ABPA patients. The median of cumulative values of FEV1 and FVC before the index year was not significantly different. After the index year, the median of cumulative data for FEV1 and FVC was significantly lower, there were significantly more hospitalization days and more days on IV antibiotics compared to controls. Comparing pre and post index year data in ABPA patients, significantly more hospitalizations and IV antibiotic days were observed after the index year. During the period preceding the index year, significantly more ABPA patients were treated with RhDnase and inhaled corticosteroids.
CONCLUSIONS: Bronchial damage cannot be considered as a facilitating factor for ABPA. ABPA causes a significant increase in bronchial damage. In ABPA patients further bronchial damage can be controlled by an increase in hospitalization days and use of IV antibiotics.. RhDnase and inhaled corticosteroids were associated with the development of ABPA. This article is protected by copyright. All rights reserved.

PMID: 29981532 [PubMed – as supplied by publisher]

Source: Industry